The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease

Fructose, especially industrial fructose (sucrose and high fructose corn syrup) is commonly used in all kinds of beverages and processed foods. Liver is the primary organ for fructose metabolism, recent studies suggest that excessive fructose intake is a driving force in non-alcoholic fatty liver di...

Full description

Bibliographic Details
Main Authors: Siyu Yu, Chunlin Li, Guang Ji, Li Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.783393/full
_version_ 1818402533139283968
author Siyu Yu
Chunlin Li
Guang Ji
Li Zhang
author_facet Siyu Yu
Chunlin Li
Guang Ji
Li Zhang
author_sort Siyu Yu
collection DOAJ
description Fructose, especially industrial fructose (sucrose and high fructose corn syrup) is commonly used in all kinds of beverages and processed foods. Liver is the primary organ for fructose metabolism, recent studies suggest that excessive fructose intake is a driving force in non-alcoholic fatty liver disease (NAFLD). Dietary fructose metabolism begins at the intestine, along with its metabolites, may influence gut barrier and microbiota community, and contribute to increased nutrient absorption and lipogenic substrates overflow to the liver. Overwhelming fructose and the gut microbiota-derived fructose metabolites (e.g., acetate, butyric acid, butyrate and propionate) trigger the de novo lipogenesis in the liver, and result in lipid accumulation and hepatic steatosis. Fructose also reprograms the metabolic phenotype of liver cells (hepatocytes, macrophages, NK cells, etc.), and induces the occurrence of inflammation in the liver. Besides, there is endogenous fructose production that expands the fructose pool. Considering the close association of fructose metabolism and NAFLD, the drug development that focuses on blocking the absorption and metabolism of fructose might be promising strategies for NAFLD. Here we provide a systematic discussion of the underlying mechanisms of dietary fructose in contributing to the development and progression of NAFLD, and suggest the possible targets to prevent the pathogenetic process.
first_indexed 2024-12-14T08:09:52Z
format Article
id doaj.art-c5add71ffb0a4a7a84fe58ab1ebd8734
institution Directory Open Access Journal
issn 1663-9812
language English
last_indexed 2024-12-14T08:09:52Z
publishDate 2021-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj.art-c5add71ffb0a4a7a84fe58ab1ebd87342022-12-21T23:10:06ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-11-011210.3389/fphar.2021.783393783393The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver DiseaseSiyu YuChunlin LiGuang JiLi ZhangFructose, especially industrial fructose (sucrose and high fructose corn syrup) is commonly used in all kinds of beverages and processed foods. Liver is the primary organ for fructose metabolism, recent studies suggest that excessive fructose intake is a driving force in non-alcoholic fatty liver disease (NAFLD). Dietary fructose metabolism begins at the intestine, along with its metabolites, may influence gut barrier and microbiota community, and contribute to increased nutrient absorption and lipogenic substrates overflow to the liver. Overwhelming fructose and the gut microbiota-derived fructose metabolites (e.g., acetate, butyric acid, butyrate and propionate) trigger the de novo lipogenesis in the liver, and result in lipid accumulation and hepatic steatosis. Fructose also reprograms the metabolic phenotype of liver cells (hepatocytes, macrophages, NK cells, etc.), and induces the occurrence of inflammation in the liver. Besides, there is endogenous fructose production that expands the fructose pool. Considering the close association of fructose metabolism and NAFLD, the drug development that focuses on blocking the absorption and metabolism of fructose might be promising strategies for NAFLD. Here we provide a systematic discussion of the underlying mechanisms of dietary fructose in contributing to the development and progression of NAFLD, and suggest the possible targets to prevent the pathogenetic process.https://www.frontiersin.org/articles/10.3389/fphar.2021.783393/fullnon-alcoholic fatty liver disease (NAFLD)fructoseintestinal environmentde novo lipogenesisinflammation
spellingShingle Siyu Yu
Chunlin Li
Guang Ji
Li Zhang
The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
Frontiers in Pharmacology
non-alcoholic fatty liver disease (NAFLD)
fructose
intestinal environment
de novo lipogenesis
inflammation
title The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
title_full The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
title_fullStr The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
title_full_unstemmed The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
title_short The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
title_sort contribution of dietary fructose to non alcoholic fatty liver disease
topic non-alcoholic fatty liver disease (NAFLD)
fructose
intestinal environment
de novo lipogenesis
inflammation
url https://www.frontiersin.org/articles/10.3389/fphar.2021.783393/full
work_keys_str_mv AT siyuyu thecontributionofdietaryfructosetononalcoholicfattyliverdisease
AT chunlinli thecontributionofdietaryfructosetononalcoholicfattyliverdisease
AT guangji thecontributionofdietaryfructosetononalcoholicfattyliverdisease
AT lizhang thecontributionofdietaryfructosetononalcoholicfattyliverdisease
AT siyuyu contributionofdietaryfructosetononalcoholicfattyliverdisease
AT chunlinli contributionofdietaryfructosetononalcoholicfattyliverdisease
AT guangji contributionofdietaryfructosetononalcoholicfattyliverdisease
AT lizhang contributionofdietaryfructosetononalcoholicfattyliverdisease